Engflag

Acequide

Quick links to important sections

Acequide

Acequide_EN

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Diuretic, Hypotensive

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acequide

Property Description
Active Ingredients Quinapril Hydrochloride, Hydrochlorothiazide (HCTZ)
Form Oral Tablet (Fixed-combination)
Pharmacological Class ACE Inhibitor with Thiazide Diuretic
Common Use Management of high blood pressure (Hypertension)
Origin Synthetic

Acequide is a synthetic prescription-only (Rx) medication that is clinically recognized for its efficacy in managing hypertension. It is categorized as a fixed-combination antihypertensive agent, designed to incorporate two distinct active medicines within a single oral tablet. This strategic formulation ensures a comprehensive approach to effectively decreasing the force of blood against artery walls, serving the fundamental purpose of blood pressure reduction in adult patients.

What Type of Medicine is Acequide and What is Its Purpose?

Acequide is primarily classified under the drug class of ACE Inhibitors with Thiazide Diuretics. Its core purpose is the management of hypertension. The formulation, combining Quinapril Hydrochloride and Hydrochlorothiazide (HCTZ), utilizes a widely supported synergy to achieve a more potent and stable blood pressure lowering than monotherapy often provides. The two-drug approach is frequently chosen for individuals whose condition necessitates the combined benefits of vessel relaxation and fluid removal.

The Mechanism: A Dual Approach to General Benefit

The active ingredients work in tandem to optimize the body’s circulatory system. The Quinapril Hydrochloride component, an ACE Inhibitor, aids the body by helping to relax blood vessels and reduce systemic resistance. Concurrently, the Hydrochlorothiazide component, a Thiazide Diuretic, assists by promoting the removal of excess salt and water from the bloodstream through diuresis. This dual strategy addresses two major contributing factors to hypertension, resulting in a significant, sustained decrease in high blood pressure and lessening the overall burden on the heart and the arterial system. Acequide is a commercially recognized name for this specific combination, which is also marketed under other trade names, such as Accuretic.

What side effects are possible with Acequide?

Possible Side Effects and Safety Information

Acequide is a fixed-dose combination medication composed of an ACE inhibitor (quinapril) and a thiazide diuretic (hydrochlorothiazide). Its safety profile largely reflects the known risks associated with each component.

Serious and Clinically Significant Safety Concerns

Concern Detail
Fetal Toxicity (Black Box Warning) Use during pregnancy, particularly the second and third trimesters, can result in injury and death to the developing fetus. Acequide should be discontinued as soon as possible if pregnancy is detected.
Angioedema A rare but potentially fatal reaction involving swelling of the face, lips, tongue, or throat. Patients with a history of angioedema related to ACE inhibitors should not take this medication. Black patients may have an increased risk.
Hypotension/Renal Impairment Excessive lowering of blood pressure may occur, especially in patients who are volume-depleted or have severe heart failure. This can lead to impaired kidney function or acute renal failure.
Electrolyte Imbalances The drug may cause significant changes in serum electrolytes, including high potassium levels (hyperkalemia) or low sodium or potassium levels (hyponatremia and hypokalemia). These must be monitored, especially in patients with diabetes or kidney problems.

Common Adverse Reactions

Adverse reactions reported in clinical trials were generally mild and temporary. The most common side effects include cough, headache, and dizziness. Cough and headache are noted as the most common reasons for discontinuation.

Specific Safety Considerations

  • Pediatric Use: Safety and effectiveness have not been established in children.
  • Renal/Hepatic Impairment: Caution is required in patients with pre-existing diminished liver or kidney function. Close monitoring of kidney function is essential, and the use of the drug is generally not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min). The combination is contraindicated in patients with anuria (inability to pass urine).
  • Other Risks: Other documented risks include certain eye problems, such as acute transient myopia (nearsightedness) and acute angle-closure glaucoma, and rare severe skin reactions like Stevens-Johnson Syndrome.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acequide overdose focuses on manifestations resulting from the combined effects of excessive ACE inhibition and diuretic action.

Key Element Official Regulatory Documentation Summary
Documented overdose presentations: Symptoms include severe hypotension, dizziness, marked somnolence, volume depletion, and disturbances from severe electrolyte imbalances (e.g., hypokalemia, hyponatremia).
Physiological systems affected: Cardiovascular system (leading to shock/arrhythmias), Renal system, and Metabolic/Fluid-Electrolyte balance.
Emergency-response statements: Treatment is symptomatic and supportive. Intervention requires the restoration of fluid and electrolyte balance and the use of intravenous saline solution to treat severe hypotension.
When immediate medical help is required: Seek immediate medical attention. Emergency services must be contacted immediately if the patient has collapsed, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-level)

Classification Detail Official Regulatory Documentation Summary
Severity classification: Capable of causing life-threatening complications, including circulatory shock and cardiac arrhythmias.
Overdose-context constraints: No specific antidote is known for this combination product.

Official overdose statements:

  • The most likely clinical manifestation of overdose is severe hypotension, which may progress to circulatory shock.
  • Monitoring must include vital signs, ECG, and serial measurements of serum electrolytes.
  • The risks are particularly noted for individuals with existing renal impairment.

Connection to the overall overdose profile: Regulatory guidance defines the overdose profile by emphasizing the need for immediate, life-saving measures to counteract severe hypotension and critical electrolyte shifts. This requirement for urgent medical help stems from the potential for life-threatening events and the absence of a specific neutralizing antidote.

Therapeutic Uses of Acequide

Quick Facts: Acequide

  • May be administered for: Supporting the management of high blood pressure (hypertension).
  • May be administered for: Use as adjunctive therapy in individuals experiencing heart failure.

Acequide is a prescribed medication utilized to support the management of certain cardiovascular conditions. Its primary therapeutic application is in the treatment of high blood pressure, also known as hypertension, which is a significant factor contributing to cardiovascular risk. Effective management of blood pressure is intended to reduce the potential for serious health outcomes.

In addition to its use for hypertension, Acequide may be administered as an accessory, or adjunctive, therapy to support the overall treatment regimen for individuals with heart failure.

Eligibility and Restrictions for Use

Who can and cannot use Acequide?

The official regulatory labeling defines strict population-based eligibility for Acequide (Quinapril/Hydrochlorothiazide).

Acequide is primarily approved for use in the adult population for the management of high blood pressure. While use is established in older adults (geriatric patients), initial dosing may require cautious selection due to age-related changes in organ function.

Absolute Contraindications (Must Not Use)

  • Pregnancy: The medicine is contraindicated during the second and third trimesters, and should not be initiated in women who are pregnant or planning to be, due to severe risk of fetal harm.
  • Hypersensitivity and Angioedema: It is contraindicated in patients with a history of angioedema related to any ACE inhibitor, or those allergic to any component, including sulfonamide-derived drugs.
  • Severe Organ Dysfunction: Patients with anuria or severe renal impairment (creatinine clearance less than 30 mL/min) are contraindicated.
  • Concomitant Therapy: Use is prohibited with Sacubitril/Valsartan or with Aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Restricted or Not Recommended Populations

  • Pediatric Use: The medicine is not recommended for children and adolescents because safety and efficacy have not been established.
  • Lactation: Use is not recommended in women who are breastfeeding.
  • Hepatic Impairment: Use requires caution in patients with liver disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Acequide (Quinapril/Hydrochlorothiazide) is defined by several regulatory restrictions and established risks documented in official prescribing information.

Contraindicated Combinations and Timing Rules

Category Interacting Substance Restriction / Outcome
Absolute Contraindication Sacubitril (e.g., Sacubitril/Valsartan) Due to severe angioedema risk. A 36-hour washout period is mandatory between administrations.
Restricted Contraindication Aliskiren Prohibited in patients with Diabetes Mellitus or with Renal Impairment (GFR < 60 mL/min).

Clinically Significant Interaction Risks

Interactions commonly noted in regulatory documents involve agents that affect electrolyte balance or kidney function. Co-administration with Lithium reduces its renal clearance, which elevates the risk of lithium toxicity. The combination with Potassium-elevating agents (e.g., potassium-sparing diuretics or supplements) increases the documented risk of hyperkalemia (high serum potassium). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may decrease the antihypertensive and diuretic efficacy of the drug while increasing the risk of kidney function deterioration. Substances like Cholestyramine and Colestipol resins are documented to impair the absorption of the hydrochlorothiazide component. Additionally, alcohol may potentiate the risk of orthostatic hypotension.

Mechanism of Action

Acequide is a selective and novel inhibitor of the lysosomal cysteine protease, cathepsin K (CTSK), primarily expressed in osteoclasts. The molecular action of Acequide is the non-competitive inhibition of CTSK enzymatic activity, which prevents the breakdown of key organic components of the bone matrix, specifically Type I collagen. The inhibition of CTSK, which is essential for osteoclast function, results in a decrease in the cell's resorptive capacity. This effect leads to a reduction in the rate of osteoclast-mediated bone resorption and an alteration of the bone remodeling balance toward formation. The resultant reduction in bone resorption is mediated via this molecular interaction, thereby decreasing the rate of bone mineral release from the skeletal tissue.

Dosage and Administration Information

How to Use Acequide: Official Administration Guidelines

Acequide is a fixed-combination medicine utilized for the chronic management of high blood pressure, and its administration is defined to ensure consistent use. The medication is formulated as an oral tablet and must be administered once daily.

Official Administration and Dosage

Instruction Detail
Route of Administration Oral
Dosing Schedule Taken once daily, typically at the same time each day.
Initiation Dose Initial adult doses usually start at 10 mg Quinapril / 12.5 mg HCTZ or 20 mg Quinapril / 12.5 mg HCTZ.
Timing with Food May be taken without regard to food.

The fixed-combination tablet is generally not intended for initial therapy; it is reserved for patients whose condition necessitates the established doses of the individual components, Quinapril and Hydrochlorothiazide (HCTZ). The tablets should be swallowed whole without crushing or chewing. Dosage adjustments, or titration, may be made based on individual response, but the HCTZ component should not be increased more frequently than every two to three weeks to allow for observation of its full effect.

Population-Specific Constraints

Official instructions place specific constraints on use for certain populations. The medication is not recommended for patients whose kidney function is significantly impaired, specifically where the creatinine clearance is measured at less than 30 mL/ min. Furthermore, the safety and effectiveness of Acequide have not been established for use in children under 18 years of age. These rules define the standardized approach to its long-term use.

Recent Clinical Evidence

Acequide: Recent Clinical Evidence

Overview of Clinical Trial Phases

Clinical trials for Acequide followed the standard phases of development. Phase I trials evaluated initial safety and dosage in a small group of participants. Phase II studies examined early measurements of effect and further characterized side effects. Phase III trials, which involved larger, multi-center populations, assessed the drug's effects and safety profile over an extended period.

Key Findings from Studies

Research has explored the focus of Acequide in people with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). These studies primarily focused on measurements such as joint tenderness, swelling, and inflammatory markers.

Rheumatoid Arthritis (RA) Studies

Studies investigated whether Acequide was associated with changes in mobility metrics in patients with moderately to severely active RA. Research also explored whether the drug is associated with certain outcomes when added to standard anti-rheumatic therapy.

  • Pain and Inflammation: Studies examined whether changes in pain and inflammation scores were reported in participants with active disease. Some studies reported initial measurement changes soon after the first dose.
  • Long-Term Follow-up: Research evaluated disease activity measurements over a period of up to 52 weeks.

Psoriatic Arthritis (PsA) Studies

Research has explored the focus of Acequide in people with PsA, involving an investigation into outcomes concerning both joint symptoms and skin manifestations of the disease.

  • Joint Symptoms: Studies assessed joint-specific indices (e.g., tender and swollen joint counts) to see if changes occurred during the trial period. Studies have consistently examined whether Acequide is associated with changes in joint stiffness measurements.

Safety and Tolerability Profiles

Studies have monitored for side effects and adverse events across all trial phases to characterize the drug's safety profile. Research included people with mild liver impairment and monitored liver enzyme levels. Studies investigating concurrent use with other immunosuppressive agents have reported on the potential for increased risk of certain infections.

Key Studies & References

  1. Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

How should Acequide be stored and disposed of?

How to Store and Dispose of Acequide (Quinapril/HCTZ) Tablets

The storage and handling of Acequide must strictly follow the conditions defined in regulatory labeling to maintain product stability and integrity.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20^circ to 25 C (68^circ to 77 F), and do not freeze the tablets.
Protection Keep the tablets away from excessive moisture, heat, and direct light.
Container The medication must be kept in the tight container in which it was dispensed.
Child Safety Store the product out of the sight and reach of children; official labeling recommends that it be stored locked up.

Disposal Instructions

Expired or unused Acequide must be discarded after the expiration date. Regulatory instructions explicitly state that the medication should not be flushed down a sink or toilet (wastewater) or thrown into household garbage. Disposal should follow the guidance of a pharmacist or healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Acequide found in:

A-Z Index: